Literature DB >> 28764885

Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.

Majuran Perinpam1, Felicity T Enders2, Kristin C Mara2, Lisa E Vaughan2, Ramila A Mehta2, Nickolay Voskoboev3, Dawn S Milliner1, John C Lieske4.   

Abstract

BACKGROUND: Since plasma oxalate (POx) concentrations increase at lower glomerular filtration rate (GFR) levels, even among those without enteric (EH) or primary hyperoxaluria (PH), the appropriate thresholds for considering a disorder of oxalate metabolism are poorly defined. The current study was completed to establish relationships between POx, GFR, and urine oxalate excretion (UOx) among patients with PH, EH, and routine urinary stone disease (USD).
METHODS: The most recent POx measurement on all Mayo Clinic patients between 2005 and 2015 were electronically pulled from the Lab Information System together with the closest serum creatinine within 14days and 24h urine study within 60days. After exclusion of patients not in steady state at the time of blood draw, 270 patients were available for study. Records were reviewed for clinical diagnoses to categorize patients as PH, EH, or USD. Waste plasma for Pox was also obtained from controls without USD undergoing clinical GFR testing.
RESULTS: In all 3 groups POx increased as eGFR fell. For any given eGFR, POx was highest in the PH group and lowest in the USD and control groups (p<0.0001). POx was also influenced by UOx excretion (reflecting total body oxalate burden, absorption from diet and endogenous production). Generalized estimating equations of POx vs eGFR revealed higher average POx levels in PH compared to EH,USD or control, and for EH compared to USD or control. GEE prediction models were created that use POx, UOx, age, and serum creatinine to estimate the probability of a PH diagnosis.
CONCLUSIONS: New models were developed to help interpret POx when considering PH in clinical practice even when it was not previously suspected and/or eGFR is reduced.
Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcium oxalate; Enteric hyperoxaluria; Glomerular filtration rate; Plasma oxalate; Primary hyperoxaluria

Mesh:

Substances:

Year:  2017        PMID: 28764885      PMCID: PMC5705406          DOI: 10.1016/j.clinbiochem.2017.07.017

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  15 in total

1.  Sensitive spectrophotometric assay for plasma oxalate.

Authors:  Paula M Ladwig; Robert R Liedtke; Timothy S Larson; John C Lieske
Journal:  Clin Chem       Date:  2005-12       Impact factor: 8.327

2.  Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures.

Authors:  D M Wilson; R R Liedtke
Journal:  Clin Chem       Date:  1991-07       Impact factor: 8.327

Review 3.  Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria.

Authors:  Zaccaria Ricci; Dinna N Cruz; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2011-03-01       Impact factor: 28.314

Review 4.  Primary hyperoxaluria.

Authors:  Víctor Lorenzo; Armando Torres; Eduardo Salido
Journal:  Nefrologia       Date:  2014-04-30       Impact factor: 2.033

5.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

6.  Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.

Authors:  Katja B P Elgstoen; Linda Flaa Johnsen; Berit Woldseth; Lars Morkrid; Anders Hartmann
Journal:  Nephrol Dial Transplant       Date:  2010-02-17       Impact factor: 5.992

Review 7.  Hereditary causes of kidney stones and chronic kidney disease.

Authors:  Vidar O Edvardsson; David S Goldfarb; John C Lieske; Lada Beara-Lasic; Franca Anglani; Dawn S Milliner; Runolfur Palsson
Journal:  Pediatr Nephrol       Date:  2013-01-20       Impact factor: 3.714

Review 8.  The primary hyperoxalurias.

Authors:  Bernd Hoppe; Bodo B Beck; Dawn S Milliner
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

9.  A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria.

Authors:  Bernd Hoppe; Craig B Langman
Journal:  Pediatr Nephrol       Date:  2003-08-15       Impact factor: 3.714

10.  Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure.

Authors:  E M Worcester; Y Nakagawa; D A Bushinsky; F L Coe
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more
  16 in total

1.  End Points for Clinical Trials in Primary Hyperoxaluria.

Authors:  Dawn S Milliner; Tracy L McGregor; Aliza Thompson; Bastian Dehmel; John Knight; Ralf Rosskamp; Melanie Blank; Sixun Yang; Sonia Fargue; Gill Rumsby; Jaap Groothoff; Meaghan Allain; Melissa West; Kim Hollander; W Todd Lowther; John C Lieske
Journal:  Clin J Am Soc Nephrol       Date:  2020-03-12       Impact factor: 8.237

2.  Oxalosis Associated With High-Dose Vitamin C Ingestion in a Peritoneal Dialysis Patient.

Authors:  Matthew R D'Costa; Nelson S Winkler; Dawn S Milliner; Suzanne M Norby; LaTonya J Hickson; John C Lieske
Journal:  Am J Kidney Dis       Date:  2019-03-22       Impact factor: 8.860

3.  Oxalate Balance in Peritoneal Dialysis Patients: A Potential Role of Dialysis-related Peritonitis.

Authors:  Natalia Stepanova; Lesya Korol; Larysa Lebid; Lyudmyla Snisar; Svitlana Savchenko
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

4.  Estimated GFR Slope Across CKD Stages in Primary Hyperoxaluria Type 1.

Authors:  Prince Singh; Lisa E Vaughan; Phillip J Schulte; David J Sas; Dawn S Milliner; John C Lieske
Journal:  Am J Kidney Dis       Date:  2022-03-16       Impact factor: 11.072

5.  Assessment of Plasma Oxalate Concentration in Patients With CKD.

Authors:  Anja Pfau; Monika Wytopil; Kinsuk Chauhan; Martin Reichel; Steve G Coca; Peter S Aronson; Kai-Uwe Eckardt; Felix Knauf
Journal:  Kidney Int Rep       Date:  2020-09-02

6.  Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies.

Authors:  Dawn S Milliner; Pierre Cochat; Sally-Anne Hulton; Jerome Harambat; Ana Banos; Bastian Dehmel; Elisabeth Lindner
Journal:  Pediatr Nephrol       Date:  2021-01-30       Impact factor: 3.714

7.  Geobiology reveals how human kidney stones dissolve in vivo.

Authors:  Mayandi Sivaguru; Jessica J Saw; James C Williams; John C Lieske; Amy E Krambeck; Michael F Romero; Nicholas Chia; Andrew L Schwaderer; Reinaldo E Alcalde; William J Bruce; Derek E Wildman; Glenn A Fried; Charles J Werth; Richard J Reeder; Peter M Yau; Robert A Sanford; Bruce W Fouke
Journal:  Sci Rep       Date:  2018-09-13       Impact factor: 4.379

8.  Secondary Oxalate Nephropathy: A Systematic Review.

Authors:  Nuttha Lumlertgul; Monchai Siribamrungwong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  Kidney Int Rep       Date:  2018-07-29

9.  Plasma Oxalate as a Predictor of Kidney Function Decline in a Primary Hyperoxaluria Cohort.

Authors:  Ronak Jagdeep Shah; Lisa E Vaughan; Felicity T Enders; Dawn S Milliner; John C Lieske
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 6.208

10.  Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: Incidence, risk factors, and effect on renal allograft function.

Authors:  Lynn D Cornell; Hatem Amer; Jason K Viehman; Ramila A Mehta; John C Lieske; Elizabeth C Lorenz; Julie K Heimbach; Mark D Stegall; Dawn S Milliner
Journal:  Am J Transplant       Date:  2021-07-26       Impact factor: 9.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.